Research
Atrial Fibrillation
- Local PI: Dr. Allan Skanes
In this trial we want to find out if aggressive management of risk factors is useful for people with your type of heart rhythm problem. This study involves managing risk factors associated with AF such as: high blood pressure (hypertension)….
- Local PI: Dr. Allan Skanes
The objective of RASTA-Cohort is to answer the following question: do patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and do they suffer…
- Local PI: Dr. Allan Skanes
Atrial fibrillation is a common heart condition that happens when the top two chambers of the heart, called the atria, beat too fast and with an irregular rhythm (fibrillation). This condition can decrease the heart’s pumping capacity, which can cause…
- Local PI: Dr. Allan Skanes
The primary objective of this study is to assess the efficacy of a patient-tailored ablation strategy guided by atrial scar mapping in addition to PVI when compared to PVI alone in subjects with PeAF. The secondary objective is to evaluate safety outcomes in patients undergoing AF ablation.
- Local PI: Dr. Habib Khan
The primary objective of the trial is to evaluate the optimal strategy to manage patients with permanent AF and HF, evaluating pharmacological therapies and P&A-CSP strategy, that reduces mortality, HF hospitalizations, reduces NT-proBNP and improves Qol. The secondary objectives of the trial are to evaluate measured responses to all strategies using biochemical changes such as NT-proBNP, 6-minute walk distance {6MWD) and impact on cardiac function (echocardiogram). Alongside these patient-driven objectives, the trial also aims to evaluate the efficacy and safety of the CSP-P&A strategy compared to pharmacological therapy.
Cardiac Devices
- Local PI: Dr. Habib Khan
The purpose of this study is to compare two pacemaker placement strategies: a) standard righ ventricular pacing (control group); and b) left bundle branch pacing (LBBP) (experimental group). Typically, patients who have heart block become…
- Local PI: Dr. Habib Khan
The PROTECT-HF trial will compare two different pacing approaches for treating patients at risk of, or who already have slow heart rates.
We will compare the standard approach for pacing, which involves placing a pacing lead into the right…
- Local PI: Dr. Habib Khan
The objective of the CONDUCT-Use study is to evaluate the efficacy of ultrasound delivery of pacing leads to the particular region of LBBA deep into the septum. LBBA recruitment will be measured using internationally standardized criterion. It is hypothesized that the use of ultrasound alongside fluoroscopy during the implantation of LBBAP leads will decrease the number of attempts needed and increase safety by reducing occurrence of septal perforation, cardiac tamponade, lead dislodgement, and lead revisions. Additionally, procedure time and radiation exposure will be minimized, providing an advantage to both patients and operators.
Genetic Arrhythmia
- Local PI: Dr. Habib Khan
Millions of people suffer due to cardiac arrest every year and in many cases, the cause of the cardiac arrest is related to a disorder of the electrical activity of the heart. Calcium Release Deficiency Syndrome (CRDS) is a new electrical heart…
- Lead PI: Dr. Habib Khan
The study aims to evaluate patients diagnosed with life-threatening cardiac rhythm or admission with heart failure who have left ventricular non-compaction seen on echocardiogram or cardiac MRI. The study intends to evaluate the…
- Local PI: Dr. Habib Khan
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). Canadian adult and pediatric electrophysiology..
- Local PI: Dr. Habib Khan
CRDS is a lethal condition which is newly described, difficult to diagnose, and lacking effective and informed therapies. It is caused by mutations in RYR2 that are loss-of-function rather than CPVT-associated gain-of-function, which…
- Local PI: Dr. Habib Khan
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD). The HiRO Hypertrophic…
Investigational Product
- Local PI: Dr. Lorne Gula
Catheter ablation will, in comparison to antiarrhythmic drug therapy reduce the composite outcome of death at any time, appropriate ICD shock after 14 days, ventricular tachycardia storm after 14 days or treated sustained ventricular tachycardia below the detection rate of the ICD for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia.
- Local PI: Dr. Habib Khan
Arrhythmogenic cardiomyopathy (ACM) is a type of inherited heart problem where the heart’s muscle is replaced by fibrous and potentially fatty tissue. People with this condition are at risk of dangerous fast heartbeats, sudden cardiac death, and heart failure. The purpose of the TaRGET study is to determine if tideglusib compared to placebo will reduce the average number of PVCs per 24 hours in ACM patients.